Literature DB >> 17911401

Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.

Nina Renlund1, Francis H O'Neill, LiHua Zhang, Yisrael Sidis, Jose Teixeira.   

Abstract

Activin receptor-like kinase-2 (Alk2) has been shown to be a promiscuous type I receptor for the transforming growth factor beta (TGFbeta) family of growth and differentiation factors, such as activin, bone morphogenetic proteins, and Müllerian inhibiting substance (MIS). We have studied the putative role of Alk2 in activin signaling using MA-10 cells, a mouse transformed Leydig cell line, in which endogenous expression of cytochrome P450 c17 hydroxylase/C17-20 lyase mRNA is inhibited by both MIS and activin A. Overexpression of Alk2 in MA-10 cells inhibited the activation of the activin-responsive CAGA-luciferase reporter and, conversely, transfection of siRNA for Alk2 increased the response. In contrast, overexpression of the MIS type II receptor in MA-10 cells increased the activin-mediated induction of CAGA-luciferase approximately fivefold, which we hypothesized occurs by MIS type II receptor sequestering endogenous Alk2. Binding experiments with (125)I-labeled activin show that the underlying mechanism of Alk2-mediated inhibition of activin signaling involves Alk2 blocking the access of activin to its type II receptor, which we show can bind Alk2 in the absence of ligand. These results show that the complement of other type I receptors in addition to the ligand-specific type I receptor can provide an important mechanism for modulating cell-specific responses to members of the TGFbeta family.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911401     DOI: 10.1677/JOE-07-0281

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  12 in total

1.  Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Authors:  Tim N Beck; Vladislav A Korobeynikov; Alexander E Kudinov; Rachel Georgopoulos; Nehal R Solanki; Magda Andrews-Hoke; Timothy M Kistner; David Pépin; Patricia K Donahoe; Emmanuelle Nicolas; Margret B Einarson; Yan Zhou; Yanis Boumber; David A Proia; Ilya G Serebriiskii; Erica A Golemis
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

Review 2.  Activin receptor-like kinases: a diverse family playing an important role in cancer.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

Review 3.  Antagonism of activin by activin chimeras.

Authors:  Uwe Muenster; Radhika Korupolu; Ratindra Rastogi; Jessica Read; Wolfgang H Fischer
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

4.  Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Makoto Ikeya; Kazuhiko Horigome; Yoshihisa Matsumoto; Hayao Ebise; Megumi Nishio; Kazuya Sekiguchi; Mitsuaki Shibata; Sanae Nagata; Shuichi Matsuda; Junya Toguchida
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

5.  Haplotype association mapping of acute lung injury in mice implicates activin a receptor, type 1.

Authors:  George D Leikauf; Vincent J Concel; Pengyuan Liu; Kiflai Bein; Annerose Berndt; Koustav Ganguly; An Soo Jang; Kelly A Brant; Maggie Dietsch; Hannah Pope-Varsalona; Richard A Dopico; Y P Peter Di; Qian Li; Louis J Vuga; Mario Medvedovic; Naftali Kaminski; Ming You; Daniel R Prows
Journal:  Am J Respir Crit Care Med       Date:  2011-02-04       Impact factor: 21.405

6.  Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Authors:  Gin-Ah Song; Hyun-Jung Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Gwan-Shik Kim; Jin-Young Choi; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

7.  Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.

Authors:  Frederick S Kaplan; Joyce A Kobori; Carmen Orellana; Inmaculada Calvo; Monica Rosello; Francisco Martinez; Berta Lopez; Meiqi Xu; Robert J Pignolo; Eileen M Shore; Jay C Groppe
Journal:  Am J Med Genet A       Date:  2015-06-11       Impact factor: 2.802

8.  Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.

Authors:  Viet Q Le; Kristi A Wharton
Journal:  Dev Dyn       Date:  2012-01       Impact factor: 3.780

9.  Differential effects of follistatin on nonhuman primate oocyte maturation and pre-implantation embryo development in vitro.

Authors:  Catherine A VandeVoort; Namdori R Mtango; Young S Lee; George W Smith; Keith E Latham
Journal:  Biol Reprod       Date:  2009-07-29       Impact factor: 4.285

10.  Constitutive WNT/beta-catenin signaling in murine Sertoli cells disrupts their differentiation and ability to support spermatogenesis.

Authors:  Pradeep S Tanwar; Tomoko Kaneko-Tarui; LiHua Zhang; Poonam Rani; Makoto M Taketo; Jose Teixeira
Journal:  Biol Reprod       Date:  2009-09-30       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.